SGLT2 Inhibitor Reduces CV, Renal Events in Type 2 Diabetes
ADA 2019-Dapagliflozin reduced CV death, hospitalization for HF, and progression of CKD among T2DM patients with a wide distribution of baselines CVD risk in DECLARE-TIMI 58.
Are Abuse-deterrent Opioids Working?
Four studies presented at PAINWeek 2016 review the success of abuse-deterrent opioid formulations in stemming abuse and non-medical use.
Depression Increases Risk of Stroke
